{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:38Z","timestamp":1788847658742,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Sports Act. Living"],"abstract":"<jats:p>The Enhanced Games are often presented as an ethically improved alternative to conventional anti-doping sport because they replace prohibition with transparency, athlete autonomy, and medical supervision. The inaugural event, held in Las Vegas in May 2026, complicates rather than confirms this framing: several winners competed without enhancement, the substances used by others were often undisclosed, and only one world record was set. Open enhancement therefore does not straightforwardly resolve the ethical problems of fairness or harm; it reorganizes competition around access to biomedical optimization, tolerance of pharmacological risk, and physician-enabled performance escalation. This model also raises a neglected question: the ethics of the spectator. If audiences knowingly consume performances built on deliberate pharmacological risk, the moral problem is no longer confined to the athlete's consent; it extends to the collective normalization of medically hazardous enhancement as entertainment. The Enhanced Games should therefore be assessed not because they introduce risk into an otherwise safe world of sport, but because they institutionalize enhancement-related risk as a structural feature of competition and convert that risk into spectacle, with spectators as active, differentiated participants in that conversion.<\/jats:p>","DOI":"10.3389\/fspor.2026.1843832","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:34:25Z","timestamp":1788845665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Watching risk: fairness, medical supervision, and the spectator problem in the enhanced games"],"prefix":"10.3389","volume":"8","author":[{"given":"Alexis","family":"Demas","sequence":"first","affiliation":[{"name":"ARGOS (Art, Research and Gestures Observed Scientifically), Neurosciences and Arts","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e801068","DOI":"10.1136\/bmj-2026-801068","article-title":"Enhanced games: bold claims, weak evidence, and serious risks","volume":"393","author":"Boardley","year":"2026","journal-title":"Br Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1466424008094806","article-title":"Sport, health and drugs: a critical re-examination of some key issues and problems","volume":"129","author":"Vidar Hanstad","year":"2009","journal-title":"Perspect Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/bjsm.2003.005249","article-title":"Why we should allow performance enhancing drugs in sport","volume":"38","author":"Savulescu","year":"2004","journal-title":"Br J Sports Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1941-6008.1000","article-title":"Enhancement in sport, and enhancement outside sport","volume":"1","author":"Douglas","year":"2007","journal-title":"Stud Ethics Law Technol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1490651","DOI":"10.3389\/fspor.2024.1490651","article-title":"The Enhanced Games: a timely injection for the International Olympic Committee","volume":"6","author":"Ekdahl","year":"2024","journal-title":"Front Sports Act Living"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1512541","DOI":"10.3389\/fspor.2025.1512541","article-title":"Safeguarding athletes and anti-doping: applying theories of vulnerability","volume":"7","author":"Schneider","year":"2025","journal-title":"Front Sports Act Living"},{"key":"B8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/17511321.2026.2632893","article-title":"Paying athletes can undermine their autonomy","volume":"20","author":"Hyde","year":"2026","journal-title":"Sport Ethics Philos"},{"key":"B9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1210\/er.2013-1058","article-title":"Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement","volume":"35","author":"Pope","year":"2014","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","article-title":"The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis","volume":"24","author":"Sagoe","year":"2014","journal-title":"Ann Epidemiol"},{"key":"B11","first-page":"1089","article-title":"Physicians\u2019 ethical dilemmas in the context of anti-doping practices","volume":"3","author":"Ekmekci","year":"2016","journal-title":"Ann Sports Med Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/bjsports-2012-091838","article-title":"Sports physicians, ethics and antidoping governance: between assistance and negligence","volume":"47","author":"Dikic","year":"2013","journal-title":"Br J Sports Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/bjsm.33.6.426","article-title":"Sport medicine and the ethics of boxing","volume":"33","author":"Leclerc","year":"1999","journal-title":"Br J Sports Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/11537530-000000000-00000","article-title":"Should performance-enhancing drugs in sport be legalized under medical supervision?","volume":"41","author":"Wiesing","year":"2011","journal-title":"Sports Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/17430437.2017.1388783","article-title":"Bracketed morality and ethical ideologies of sport fans","volume":"21","author":"Smith","year":"2018","journal-title":"Sport Soc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"673452","DOI":"10.3389\/fspor.2021.673452","article-title":"Efficient ways to combat doping in a sports education context!? A systematic review on doping prevention measures focusing on young age groups","volume":"3","author":"P\u00f6ppel","year":"2021","journal-title":"Front Sports Act Living"}],"container-title":["Frontiers in Sports and Active Living"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1843832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:34:26Z","timestamp":1788845666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fspor.2026.1843832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":16,"alternative-id":["10.3389\/fspor.2026.1843832"],"URL":"https:\/\/doi.org\/10.3389\/fspor.2026.1843832","relation":{},"ISSN":["2624-9367"],"issn-type":[{"value":"2624-9367","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1843832"}}